"Leukotriene Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level.
Descriptor ID |
D020024
|
MeSH Number(s) |
D06.347.565 D27.505.696.399.450.565
|
Concept/Terms |
Leukotriene Antagonists- Leukotriene Antagonists
- Receptor Antagonists, Leukotriene
- Antagonists, Leukotriene Receptor
- Leukotriene Receptor Antagonists
- Antagonists, Leukotriene
|
Below are MeSH descriptors whose meaning is more general than "Leukotriene Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Leukotriene Antagonists".
This graph shows the total number of publications written about "Leukotriene Antagonists" by people in this website by year, and whether "Leukotriene Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 |
2007 | 0 | 1 | 1 |
2009 | 1 | 0 | 1 |
2010 | 0 | 1 | 1 |
2016 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leukotriene Antagonists" by people in Profiles.
-
Chen Y, Shan Y, Lu M, DeSouza N, Guo Z, Hoffman R, Liang A, Li S. Alox5 Blockade Eradicates JAK2V617F-Induced Polycythemia Vera in Mice. Cancer Res. 2017 01 01; 77(1):164-174.
-
Wixted JJ, Fanning P, Rothkopf I, Stein G, Lian J. Arachidonic acid, eicosanoids, and fracture repair. J Orthop Trauma. 2010 Sep; 24(9):539-42.
-
Wixted JJ, Fanning PJ, Gaur T, O'Connell SL, Silva J, Mason-Savas A, Ayers DC, Stein GS, Lian JB. Enhanced fracture repair by leukotriene antagonism is characterized by increased chondrocyte proliferation and early bone formation: a novel role of the cysteinyl LT-1 receptor. J Cell Physiol. 2009 Oct; 221(1):31-9.
-
Harrold LR, Patterson MK, Andrade SE, Dube T, Go AS, Buist AS, Chan KA, Weller PF, Wechsler ME, Yood RA, Davis KJ, Platt R, Walker AM. Asthma drug use and the development of Churg-Strauss syndrome (CSS). Pharmacoepidemiol Drug Saf. 2007 Jun; 16(6):620-6.
-
Altman LC, Munk Z, Seltzer J, Noonan N, Shingo S, Zhang J, Reiss TF. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group. J Allergy Clin Immunol. 1998 Jul; 102(1):50-6.
-
Drazen JM, Lilly CM, Sperling R, Rubin P, Israel E. Role of cysteinyl leukotrienes in spontaneous asthmatic responses. Adv Prostaglandin Thromboxane Leukot Res. 1994; 22:251-62.